GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

TSH Biopharm Corp 8432.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

61.40

+4.60%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in TWD, from our data supplier.

FY2025

Revenue

TWD 1.34bn

FY2016FY2025

Net income

TWD 139.3m

FY2016FY2025

Free cash flow

TWD 129.1m

FY2016FY2025

Shareholders' equity

TWD 1.44bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueTWD 1.34bnTWD 1.12bnTWD 810.9mTWD 741.1mTWD 413.5mTWD 447.9mTWD 507.7mTWD 515.6mTWD 486.3mTWD 492.5m
Gross profitTWD 680.7mTWD 582.8mTWD 399.9mTWD 389.9mTWD 247.4mTWD 285.2mTWD 314.7mTWD 334.4mTWD 317.3mTWD 321.1m
Research and developmentTWD 24.6mTWD 28.0mTWD 24.8mTWD 31.1mTWD 23.5mTWD 28.7mTWD 52.8mTWD 96.8mTWD 74.4mTWD 115.9m
Operating incomeTWD 219.3mTWD 170.6mTWD 74.8mTWD 85.0mTWD 61.5mTWD 77.2mTWD 56.2mTWD 56.1mTWD 70.9mTWD 30.8m
Net incomeTWD 139.3mTWD 113.1mTWD 62.0mTWD 61.9mTWD 47.1mTWD 61.6mTWD 85.3mTWD 57.8mTWD 65.0mTWD 141.2m
Diluted earnings per share3.582.901.621.611.231.602.191.481.673.67

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsTWD 1.95bnTWD 1.84bnTWD 1.40bnTWD 1.44bnTWD 1.17bnTWD 1.23bnTWD 1.26bnTWD 1.22bnTWD 1.28bnTWD 1.57bn
Cash and short-term investments——TWD 772.1mTWD 815.8mTWD 733.4mTWD 725.7m———TWD 858.5m
Total liabilitiesTWD 233.8mTWD 219.2mTWD 133.6mTWD 222.5mTWD 85.8mTWD 103.0mTWD 138.8mTWD 99.4mTWD 135.1mTWD 116.9m
Debt——TWD 7.8mTWD 63.9mTWD 5.0mTWD 10.3m————
Shareholders' equityTWD 1.44bnTWD 1.39bnTWD 1.11bnTWD 1.14bnTWD 1.08bnTWD 1.13bnTWD 1.12bnTWD 1.12bnTWD 1.15bnTWD 1.45bn
Shares outstanding39m39m38m38m38m38m39m39m39m38m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsTWD 139.5mTWD 183.8mTWD 33.9mTWD 34.4mTWD 68.7mTWD 11.6mTWD 88.6mTWD 62.6mTWD 81.1mTWD 42.8m
Capital spending−TWD 10.4m−TWD 2.7m−TWD 5.6m−TWD 18.7m−TWD 382,000−TWD 2.4m−TWD 3.0m−TWD 5.9m−TWD 4.6m−TWD 1.8m
Free cash flowTWD 129.1mTWD 181.0mTWD 28.3mTWD 15.6mTWD 68.3mTWD 9.2mTWD 85.7mTWD 56.7mTWD 76.6mTWD 41.1m
Dividends paid−TWD 81.4m−TWD 49.1m−TWD 61.4m−TWD 57.6m−TWD 69.1m−TWD 69.1m−TWD 61.4m−TWD 80.6m−TWD 119.0m−TWD 80.6m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueTWD 330.7mTWD 285.8mTWD 357.5mTWD 422.6mTWD 269.3mTWD 287.1mTWD 291.1mTWD 388.5m
Gross profitTWD 183.5mTWD 156.5mTWD 179.4mTWD 202.1mTWD 148.9mTWD 150.3mTWD 145.6mTWD 188.3m
Operating incomeTWD 73.2mTWD 51.7mTWD 42.2mTWD 84.2mTWD 48.3mTWD 42.9mTWD 27.0mTWD 74.7m
Net incomeTWD 45.8mTWD 38.7mTWD 23.8mTWD 58.8mTWD 26.2mTWD 30.4mTWD 9.6mTWD 48.5m
Diluted earnings per share1.180.990.611.530.670.780.251.25
Cash from operationsTWD 43.0mTWD 166.0mTWD 40.0m—TWD 42.0mTWD 26.0mTWD 76.0mTWD 36.0m
Capital spending—−TWD 4.0m−TWD 1.0m—−TWD 3.0m−TWD 5.0m−TWD 1.0m—
Free cash flow—TWD 162.0mTWD 39.0m—TWD 39.0mTWD 21.0mTWD 75.0m—
Total assetsTWD 2.03bnTWD 1.98bnTWD 1.95bnTWD 2.02bnTWD 1.85bnTWD 1.88bnTWD 1.84bnTWD 1.91bn
Cash and short-term investments———TWD 914.5m————
Debt———TWD 8.1m————
Shareholders' equityTWD 1.41bnTWD 1.48bnTWD 1.44bnTWD 1.44bnTWD 1.34bnTWD 1.40bnTWD 1.39bnTWD 1.40bn

Financial ratios

Data as of 29 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin50.9%52.2%49.3%52.6%59.8%63.7%
Operating margin17.6%15.6%9.2%11.5%14.9%17.2%
Net margin10.4%10.1%7.6%8.4%11.4%13.7%
Return on equity9.7%8.1%5.6%5.4%4.3%5.5%
Return on assets7.1%6.1%4.4%4.3%4.0%5.0%
Free cash flow yield—8.7%1.9%2.5%3.3%0.7%
Revenue growth19.8%37.6%9.4%79.2%-7.7%-11.8%
Earnings growth23.1%82.4%0.2%31.4%-23.5%-27.8%
Current ratio6.27x6.25x8.33x5.56x10.72x9.57x
Debt to equity—0.00x0.01x0.05x0.00x0.01x
Equity ratio73.9%75.6%79.1%79.2%92.7%91.6%
Interest coverage295.59x381.34x108.79x121.57x769.11x2857.63x
R&D as a share of sales1.8%2.5%3.1%4.2%5.7%6.4%
Buybacks as a share of market value—-1.5%0.1%0.0%0.0%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue21.7%24.4%10.0%
Operating income37.2%23.2%19.5%
Net income31.0%17.7%5.3%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin51.5%51.3%53.1%57.0%
Operating margin15.9%13.7%14.1%12.7%
Net margin10.3%9.4%10.0%12.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings16.421.131.129.536.336.735.849.035.419.6
Price to sales1.72.12.42.54.15.06.05.54.75.6

Dividends and splits

Per share, in the currency the company pays

Paid for 4 years. Last went ex-dividend on 16 Jun 2025.

FY2025FY2024FY2023FY2022
Paid in the year2.121.281.601.50
  • 1.1-for-1 split · 28 Aug 2013
  • 1.1-for-1 split · 22 Aug 2012

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.